Manager TitleAgeSince
President - 29/07/2025
Compliance Officer - -
Chief Tech/Sci/R&D Officer - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.12%+2.57% - - 1.8B
-2.54%+1.31%+54.27%+117.14% 1,135B
-1.42%+3.23%+38.56%+74.05% 635B
+0.16%+0.08%+25.29%+96.64% 505B
+1.55%+4.66%+48.77%+67.67% 378B
-1.34%-0.47%+66.04%+40.18% 358B
-0.27%+2.61%+23.54%+49.77% 295B
+0.94%+4.40%+3.19%+24.58% 266B
-1.79%+1.57%+50.56%+61.40% 237B
-0.73%-0.10%+29.02%+99.06% 193B
Average -0.33%+1.60%+37.69%+70.05% 444.85B
Weighted average by Cap. -1.00%+1.63%+41.56%+80.86%
Logo Endo, Inc.
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
Employees
3,116
  1. Stock Market
  2. Stocks
  3. NDOI Stock